Results 81 to 90 of about 24,685 (174)

Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis: A Single-Center US-based Series. [PDF]

Clin Infect Dis, 2023
Meyerowitz EA, Mukerji SS, Kyle Harrold G, Erdil RM, Chen ST, Rudmann EA, Tsibris A, Venna N, Robbins GK.   +8 more
europepmc   +1 more source

[Retracted] Effects of nutrients on matrix metalloproteinases in human T‑lymphotropic virus type 1 positive and negative malignant T‑lymphocytes. [PDF]

Int J Oncol, 2023
Harakeh S, Abou-Khouzam R, Damanhouri GA, Al-Hejin A, Kumosani T, Niedzwiecki A, Rath M, Barbour E, Diab-Assaf M, Azar R.   +9 more
europepmc   +1 more source

The Clinical Pathway of Human T-Lymphotropic Virus Type-1 (HTLV-1) from Infection to Leukemia: A Comprehensive Review

Experimed
Human T-lymphotropic virus type 1 (HTLV-1), a member of the Retroviridae family, is a pathogenic retrovirus that primarily includes two clinically relevant types: HTLV-1 and HTLV-2. HTLV-1 is etiologically linked to adult T-cell leukemia/lymphoma (ATLL),
Zahra Ghahremani, Kosar Hosseini-karkaj, Mehrdad Pashazadeh, Abolfazl Jafarı-sales, Aylin Golestani, Kosar Soleymanpour, Hossein Bannazadeh Baghi, Parya Rouhi, Mohaddeseh Bahmani   +8 more
doaj   +1 more source

Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection. [PDF]

Clin Microbiol Rev, 2022
Legrand N, McGregor S, Bull R, Bajis S, Valencia BM, Ronnachit A, Einsiedel L, Gessain A, Kaldor J, Martinello M.   +9 more
europepmc   +1 more source

Immigrating and vicinity are not risk factors in the prevalence and transmission rate of human T-lymphotropic virus type 1: A Survey in an endemic region of Iran and Afghan refugees. [PDF]

PLOS Glob Public Health, 2023
Mahdifar M, Akbari-Eidgahi MR, Mosavat A, Pourreza A, Akbarin MM, Valizadeh N, Rezaee SA, Rafatpanah H.   +7 more
europepmc   +1 more source

Human T-lymphotropic virus type 1 and novel coronavirus disease 2019; More complex than just a simple coinfection. [PDF]

Gene, 2022
Sajjadi S, Hejazi S, Ravanshad S, Jafarzadeh Esfehani R.   +3 more
europepmc   +1 more source

Case Report: Relevance of an Accurate Diagnosis and Monitoring of Infective Dermatitis Associated With Human T-Lymphotropic Virus Type 1 in Childhood. [PDF]

Front Med (Lausanne), 2021
Benencio P, Ducasa N, Arruvito L, Irurzun I, Praino L, Lamberti M, Beraza M, Berini C, Biglione M.   +8 more
europepmc   +1 more source

Diversity of HLA-A2-Restricted and Immunodominant Epitope Repertoire of Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Protein: Novel Insights among N-Terminal, Central and C-Terminal Regions. [PDF]

Biomolecules, 2023
Pereira-Santos TA, da Rocha AS, Lopes-Ribeiro Á, Corrêa-Dias LC, Melo-Oliveira P, Reis EVS, da Fonseca FG, Barbosa-Stancioli EF, Tsuji M, Coelho-Dos-Reis JGA.   +9 more
europepmc   +1 more source

Identification of hub genes and molecular pathways in human T-lymphotropic virus type 1 associated diseases using protein-protein interactions networks. [PDF]

Iran J Microbiol, 2022
Ebadi A, Momenifar N, Yazdani S, Gholizadeh O, Poortahmasebi V.   +4 more
europepmc   +1 more source

Health-Related Quality of Life Evaluation Using the Short Form-36 in Patients With Human T-Lymphotropic Virus Type 1-Associated Myelopathy. [PDF]

Front Med (Lausanne), 2022
Kimura M, Yamauchi J, Sato T, Yagishita N, Araya N, Aratani S, Tanabe K, Horibe E, Watanabe T, Coler-Reilly A, Nagasaka M, Akasu Y, Kaburagi K, Kikuchi T, Shibata S, Matsumoto H, Koseki A, Inoue S, Takata A, Yamano Y.   +19 more
europepmc   +1 more source